Physician profile
Timothy E Freyaldenhoven
NPI 1174520258
$28,407.77
in general payments reported to CMS, 2019-2025
64 companies · $4,683 in 2025
The $4,683 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,546 · 2020: $3,087 · 2021: $3,527 · 2022: $4,234 · 2023: $4,689 · 2024: $5,640 · 2025: $4,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $125 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,867.74 |
| Education | $124.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,771.63 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Novartis Pharmaceuticals Corporation | $1,622.59 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $1,529.32 | 2019-2025 | |
| Abbvie INC. | $1,523.04 | 2019-2025 | |
| Amgen INC. | $1,510.31 | 2019-2025 | Uplizna, Aimovig |
| Emd Serono, INC. | $1,324.38 | 2019-2025 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $1,286.60 | 2020-2025 | |
| Ucb, INC. | $1,249.47 | 2020-2025 | Rystiggo, Zilbrysq, Briviact |
| Mdd US Operations, LLC | $1,218.67 | 2019-2025 | Gocovri, Xadago, Myobloc |
| Pfizer INC. | $1,197.33 | 2019-2025 | |
| Lundbeck LLC | $1,081.60 | 2020-2025 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $945.83 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Supernus Pharmaceuticals, INC. | $745.02 | 2019-2021 | |
| Kyowa Kirin, INC. | $725.30 | 2019-2024 | Nourianz |
| Lilly USA, LLC | $715.01 | 2019-2025 | Emgality, Amyvid, Kisunla |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $701.56 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $682.76 | 2022-2025 | Ingrezza, Ongentys |
| Eisai INC. | $592.24 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $543.37 | 2019-2025 | Ultomiris |
| Upsher-Smith Laboratories LLC | $534.72 | 2019-2023 | |
| Csl Behring | $519.77 | 2019-2025 | Hizentra |
| Acadia Pharmaceuticals INC | $492.65 | 2019-2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company Ltd. | $489.95 | 2022 | |
| Harmony Biosciences LLC | $405.03 | 2020-2025 | Wakix |
| Biohaven Pharmaceuticals, INC. | $398.13 | 2020-2021 | |
| Tg Therapeutics, INC. | $298.64 | 2023-2025 | |
| Allergan, INC. | $280.45 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $275.19 | 2019 | |
| Celgene Corporation | $251.02 | 2021-2024 | Zeposia |
| Argenx US, INC. | $249.86 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $244.62 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $231.85 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Acorda Therapeutics, INC | $199.00 | 2019 | |
| Neurelis, INC. | $190.98 | 2021-2025 | Valtoco |
| Impel Pharmaceuticals INC. | $183.96 | 2022-2023 | Trudhesa |
| Mallinckrodt Hospital Products INC. | $178.64 | 2020-2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $168.96 | 2020-2021 | |
| Inspire Medical Systems, INC. | $157.23 | 2022-2024 | Inspire |
| Tanabe Pharma America, INC. | $135.36 | 2022-2024 | |
| Livanova USA, INC. | $130.27 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Axsome Therapeutics, INC. | $126.12 | 2023-2025 | Sunosi |
| Astrazeneca Pharmaceuticals Lp | $120.89 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $110.76 | 2022 | |
| Alnylam Pharmaceuticals INC. | $103.03 | 2019-2024 | Onpattro |
| Grifols USA, LLC | $97.69 | 2019-2025 | Gamunex-C |
| Avanir Pharmaceuticals, INC. | $88.73 | 2019-2022 | |
| Nevro Corp. | $84.37 | 2022-2024 | Senza |
| Banner Life Sciences, LLC | $78.68 | 2022-2023 | |
| Genentech USA, INC. | $77.99 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Otsuka America Pharmaceutical, INC. | $74.31 | 2025 | Rexulti |
| Adamas Pharmaceuticals, INC. | $68.10 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $58.39 | 2019-2020 | |
| Zoll Respicardia, INC. | $57.37 | 2023 | Remede System |
| Avadel Cns Pharmaceuticals, LLC | $46.98 | 2024 | Lumryz |
| Ge Healthcare | $35.97 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $34.34 | 2023 | Fycompa |
| Ipsen Biopharmaceuticals, INC | $32.41 | 2024 | Dysport |
| Avion Pharmaceuticals | $30.67 | 2022 | |
| Averitas Pharma INC. | $23.99 | 2024 | Qutenza |
| Abbott Laboratories | $16.47 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.12 | 2024 | Dojolvi |
| Resmed Corp | $14.65 | 2022 | |
| Globus Medical, INC. | $14.10 | 2025 | Omnia |
| Idorsia Pharmaceuticals US INC | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Freyaldenhoven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.